Previous 10 | Next 10 |
According to informed sources, Medtronic (NYSE: MDT ) has made an offer for sinus implant developer Intersect ENT (NASDAQ: XENT ). More news on: Medtronic plc, Intersect ENT, Inc., Healthcare stocks news, Stocks on the move, Merger & acquisition news, Read more ...
Analysis Also Confirms Treatment with PROPEL Provides Improved Patient Outcomes Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced the results of a United Kingdom-based independent analysis mea...
Intersect ENT®, Inc. (Nasdaq: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that the Centers for Medicare and Medicaid Services (CMS) has approved SINUVA® (mometasone furoate) Sinus Implant for transitional pass-th...
Intersect ENT, Inc. (Nasdaq: XENT ), today announced that management will participate in a virtual fireside chat at the William Blair 40 th Annual Growth Stock Conference. The fireside chat will take place on Thursday, June 11, 2020 at 8:00 a.m. CDT. To access the webcast, go to the "In...
Image source: The Motley Fool. Intersect ENT (NASDAQ: XENT) Q1 2020 Earnings Call May 11, 2020 , 4:30 p.m. ET Operator Continue reading
Intersect ENT, Inc. (XENT) Q1 2020 Earnings Conference Call May 11, 2020 16:30 PM ET Company Participants Tom West - President and Chief Executive Officer Richard Meier - Executive Vice President and Chief Financial Officer Conference Call Participants Robbie Marcus - JPMor...
Intersect ENT (NASDAQ: XENT ): Q1 GAAP EPS of -$0.54 misses by $0.08 . More news on: Intersect ENT, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today reported financial results for the first quarter ended March 31, 2020. First Quarter 2020 Overview Revenue of $19.8 million in the first q...
Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced that it has closed a $65 million convertible notes financing with a fund managed by Deerfield Management Company L.P. (“Deerfield...
Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced the Company has rescheduled a conference call to discuss its first quarter 2020 financial results to 4:30 p.m. ET on Monday, May 11, 2020. ...
News, Short Squeeze, Breakout and More Instantly...
Data from first-of-its-kind study published in Current Medical Research and Opinion Patients receiving PROPEL ® following endoscopic sinus surgery had statistically significant lower healthcare resource utilization over a postoperative period of 18 months, including a...
Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today reported financial results for the third quarter ended September 30, 2021. Total revenue was $24.4 million for the third qu...
Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Helios Dr. Horst Schmidt Kliniken Wiesbaden in Germany was the first hospital outside the United States to...